Overview: NOTCH3 Mutation TestIntroduction: The NOTCH3 Mutation Test detects NOTCH3 mutations to diagnose CADASIL, causing stroke or dementia. Following 2023 AAN guidelines, it uses PCR for high specificity, supporting neurological screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in molecular pathology for patients with suspected cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL).
Other Names: CADASIL Assay, NOTCH3 Gene Test.
FDA Status: Laboratory-developed test (LDT), meeting molecular pathology standards for diagnostic accuracy.
Historical Milestone: NOTCH3 mutation testing began in the 1990s with CADASIL research. PCR methods improved in the 2000s, enhancing diagnostic precision.
Purpose: Detects NOTCH3 mutations to diagnose CADASIL, guides treatment, and evaluates patients with stroke or dementia.
Test Parameters: 1. NOTCH3 Gene Mutation
Pretest Condition: No fasting required. Collect whole blood, buccal swab, or saliva. Report history of stroke, dementia, or neurological symptoms.
Specimen: Whole Blood (EDTA, 2-5 mL), Buccal Swab (sterile swab, 1-2 swabs), Saliva (sterile container, 1-2 mL). Transport in a biohazard container.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 48 hours
Sample Stability at Frozen: Not frozen
Medical History: Document stroke, dementia, migraines, or family history of CADASIL. Include current medications, especially antiplatelets.
Consent: Written consent required, detailing the tests purpose, CADASIL implications, and risks of sample collection.
Procedural Considerations: Uses PCR to detect NOTCH3 mutations in specimens. Results are available in 3-5 days, supporting clinical decisions. Performed in laboratories, often for CADASIL diagnosis.
Factors Affecting Result Accuracy: Low DNA yield or improper sample storage can affect results. Contamination may reduce specificity.
Clinical Significance: Positive NOTCH3 mutations confirm CADASIL, guiding supportive care or genetic counseling. Negative results may require further neurological testing.
Specialist Consultation: Consult a neurologist or geneticist for result interpretation and treatment planning.
Additional Supporting Tests: Brain MRI, skin biopsy, or cognitive testing to confirm CADASIL diagnosis.
Test Limitations: Not all CADASIL cases show NOTCH3 mutations; clinical correlation is needed. Sample quality affects sensitivity.
References: AAN CADASIL Guidelines, 2023; Neurology, Joutel A, 2022.
